Adas .2022 .The infection risks of JAK inhibition. ” Expert Review of Clinical Immunology, 2014323(3) : 253-261.
Szekanecz . .Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. ” Nature Reviews Rheumatology, 20(2024) : 101-115.
Cohen . .“Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. ” Annals of the Rheumatic Diseases, 76(2017) : 1253-1262.
Van de Putte L.B.A. .2004 .Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. ” Annals of the Rheumatic Diseases, 63(5) : 508-516.
Almoallim ,Hani M.,Laila A.,Alharbi A. .2014 .Rheumatoid arthritis in Saudi Arabia. Saudi Medical Journal, 35(12) : 1442-1454.
Kremer ,Joel M. . .Postapproval comparative safety study of tofacitinib and biological Disease‐Modifying Antirheumatic drugs: 5‐Year results from a United Statesbased rheumatoid arthritis Registry.” ACR Open Rheumatology. , 3(2021) : 232-184.
Choi Se,Rim Se,July Se .2025 .Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study. ” Arthritis Research & Therapy, 25(1) : .
Contreras . .Emergency department utilization by persons with rheumatoid arthritis: a population-based cohort study. Rheumatology International, 44(9) : 1691-1700.